

AP2S1 WT												
Protein Accession	Peptide	Start	End	-10lgP	Mass	Length	ppm	m/z	z	PTM	AScore	
Q00000 HA-AP2S1 WT_HUMAN	R.F(+224.15)ILIQNR.A	4	10	36.06	1126.686	7	-0.1	564.3503	2	TMT	F1:TMT:1000.00	
Q00000 HA-AP2S1 WT_HUMAN	R.FILIQNRAGK(+224.15)TR.L	4	15	25.31	1639.989	12	-1.3	547.6694	3	TMT	K10:TMT:62.82	
Q00000 HA-AP2S1 WT_HUMAN	R.LAK(+224.15)WYMQFDDDD.E	16	26	56.57	1654.77	11	-2.4	828.3904	2	TMT	K3:TMT:11.10	
Q00000 HA-AP2S1 WT_HUMAN	R.L(+224.15)AKWYIM(+15.99)QFDDDD.E	16	26	46.53	1670.765	11	-1.2	836.3888	2	TMT; Oxidation (M)	L1:TMT:0.00;M6:Oxidation (M):1000.00	
Q00000 HA-AP2S1 WT_HUMAN	R.D(+224.15)AKHTNFVEFR.N	43	53	73.05	1586.82	11	0.1	529.9474	3	TMT	D1:TMT:22.85	
Q00000 HA-AP2S1 WT_HUMAN	R.D(+224.15)AKHTNFVEFR.R	43	52	34.02	1430.719	10	-3.5	716.3644	2	TMT	D1:TMT:8.22	
Q00000 HA-AP2S1 WT_HUMAN	R.DAK(+224.15)HTN(+.98)FVEFR.N	43	53	66.38	1587.804	11	-3.1	530.2738	3	TMT; Deamidation (NQ)	K3:TMT:14.04;N6:Deamidation (NQ):1000.00	
Q00000 HA-AP2S1 WT_HUMAN	R.NFK(+224.15)IYR.R	54	60	38.06	1176.702	7	-1.6	589.3573	2	TMT	K3:TMT:39.76	
Q00000 HA-AP2S1 WT_HUMAN	R.N(+.98)(+224.15)FKIYR.R	54	60	25.57	1177.686	7	-1.7	589.8492	2	Deamidation (NQ); TMT	N1:Deamidation (NQ):1000.00;N1:TMT:0.00	
Q00000 HA-AP2S1 WT_HUMAN	R.ETSQTK(+224.15)VLK(+224.15)QLL.M	125	136	45.16	1835.113	12	1	612.7123	3	TMT	K6:TMT:39.44;K9:TMT:77.91	
Q00000 HA-AP2S1 WT_HUMAN	R.ETSQTK(+224.15)VLK.Q	125	133	46.18	1256.734	9	0.3	629.3745	2	TMT	K6:TMT:22.69	

  

AP2S1 R10W												
Protein Accession	Peptide	Start	End	-10lgP	Mass	Length	ppm	m/z	z	PTM	AScore	
Q00001 HA-AP2S1 R10W_HUMAN	R.FILIQNWAGK(+224.15)TR.L	4	15	58.93	1669.967	12	-1.1	835.9897	2	TMT	K10:TMT:181.94	
Q00001 HA-AP2S1 R10W_HUMAN	R.L(+224.15)AKWYMQFDDDD.E	16	26	43.37	1654.77	11	0.5	828.3928	2	TMT	L1:TMT:0.00	
Q00001 HA-AP2S1 R10W_HUMAN	R.DAK(+224.15)HT(+79.96)NFVEFR.N	43	53	74.34	1666.777	11	0.9	556.6002	3	TMT; Sulfation	K3:TMT:8.22;T5:Sulfation:1000.00	
Q00001 HA-AP2S1 R10W_HUMAN	R.D(+224.15)AKHT(+79.96)NFVEFR.N	43	53	70.15	1666.777	11	0.9	556.6002	3	TMT; Sulfation	D1:TMT:0.00;T5:Sulfation:1000.00	
Q00001 HA-AP2S1 R10W_HUMAN	R.D(+224.15)AKHTNFVEFR.N	43	53	68.29	1586.82	11	-0.4	529.9472	3	TMT	D1:TMT:14.04	
Q00001 HA-AP2S1 R10W_HUMAN	R.DAK(+224.15)HTN(+.98)FVEFR.N	43	53	42.32	1587.804	11	3.4	530.2772	3	TMT; Deamidation (NQ)	K3:TMT:0.00;N6:Deamidation (NQ):1000.00	
Q00001 HA-AP2S1 R10W_HUMAN	R.N(+224.15)FKIYR.R	54	60	22.03	1176.702	7	-4.9	393.2393	3	TMT	N1:TMT:24.32	
Q00001 HA-AP2S1 R10W_HUMAN	R.NFK(+224.15)IYR.R	54	60	35.87	1176.702	7	-0.9	589.3577	2	TMT	K3:TMT:36.05	
Q00001 HA-AP2S1 R10W_HUMAN	R.ETSQTK(+224.15)VLK(+224.15)QLL.M	125	136	39.05	1835.113	12	3.8	612.714	3	TMT	K6:TMT:45.16;K9:TMT:81.34	

**Supplementary Table 2.** Table indicating the AScore (confidence in localisation) of all the peptides that were identified in carrying a TMT0 label. Unhighlighted rows indicate peptides containing TMT0 labelled lysine residues. Yellow highlighted rows indicate non-lysine TMT0 labelled residues that have an AScore >20 and thus meet the confidence level set for localisation; such residues could represent N-termini. Grey highlighted rows indicate non-lysine TMT0 labelled residues that have an AScore <20 and thus there is not enough evidence in terms of the number of MS fragment ions for the software to confidently assign the TMT0 label to the residue.